InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: None

Thursday, 01/17/2019 6:45:29 AM

Thursday, January 17, 2019 6:45:29 AM

Post# of 424005
The problem with shorting AMRN...thesis...

It's really stupid for the following reasons:
1) Vascepa WON NCE in Federal Court because the FDA was WRONG

2) VascepaWON First Amendment ANCHOR case because the FDA was WRONG

3) Amarin did not prosecute the FDA for illegal rescindment of SPA, Amarin made a huge mistake by not doing this. Amarin made a mistake the FDA literal got away with murder.

4) REDUCE-IT results far exceeded ALL expectations including the principal investigator!!!!

5) #4 proves #3 FDA harms, ANCHOR population morbidity and mortality

6) Amarin has pending ITC win in Federal Court of Appeals IMO

7) Amarin has pending Generic lawsuit ending in Nevada Federal Court IMO

8) Amarin has pending victory in California Federal Courts Central & Southern districts regarding two supplement companies that used R-I to puff the claims of their supplements, this is allegedly illegal false advertising.

9) Buyout or M&A rumors or possibilites

10) The chance Amarin announces to take Europe market

For the above listed 10 reasons, shorting AMRN is a very bad idea. There's several unknowns that could margin call your position.

BB

I do not pump Amarin stock. I am not an Amarin cheerleader. If I see something I don't like I make it known. Patients come first, always!!!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News